IGMS(Delisted)
IGM Biosciences·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 0
Bearish signal 2
Bearish Abandoned Baby
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IGMS
Igm Biosciences, Inc.
A clinical-stage biotech company focused on creating and developing IgM antibodies
325 E. Middlefield Road, Mountain View, CA 94043
--
IGM Biosciences, Inc., was incorporated in Delaware in August 1993 under the name Palingen, Inc. IGM Biosciences, Inc., is a biotechnology company developing IgM antibody therapies for the treatment of cancer.
Company Financials
EPS
IGMS has released its 2025 Q2 earnings. EPS was reported at 1.58, versus the expected -0.36, beating expectations. The chart below visualizes how IGMS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
IGMS has released its 2025 Q2 earnings report, with revenue of 143.62M, reflecting a YoY change of 11353.19%, and net profit of 97.58M, showing a YoY change of 303.72%. The Sankey diagram below clearly presents IGMS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
